FDA Approves Freenome's SimpleScreen CRC Blood Test for Colorectal Cancer Screening, Abbott to Exclusively Market
Freenome Receives FDA Approval for Colorectal Cancer Blood Test
The U.S. Food and Drug Administration (FDA) has officially approved Freenome's blood-based colorectal cancer screening product, 'SimpleScreen™ CRC,' on July 27, 2026. This approval marks a significant milestone in the industry, as it offers a non-invasive method for early detection of colorectal cancer in average-risk individuals aged 45 and older, using only a blood sample. The key regulatory approval factor is its ability to address the low compliance and reluctance associated with traditional colonoscopies, maximizing patient convenience through a simple blood test. This is expected to revolutionize the paradigm of preventive medicine by providing a new alternative for approximately 60 million Americans who are not undergoing screening due to limited access to healthcare.
Data Validation through the PREEMPT CRC Clinical Trial
The basis for this approval is the 'PREEMPT CRC' clinical trial, the largest prospective clinical trial to date, involving over 48,000 asymptomatic, average-risk adults. According to the prespecified analysis results, SimpleScreen CRC demonstrated a sensitivity of 81.1% and a specificity of 90.4% for detecting colorectal cancer, based on patients without colorectal tumors. However, the sensitivity for advanced precancerous lesions (APL) was only 13.7%, clearly demonstrating the limitations of liquid biopsy in detecting early-stage cancers. Nevertheless, the sensitivity for high-grade dysplasia lesions reached 30.7%, suggesting the potential for increased follow-up colonoscopies in high-risk groups.
Abbott's Exclusive Marketing and Synergy with Exact Sciences Acquisition
The U.S. distribution and marketing of SimpleScreen CRC will be exclusively handled by Abbott (ABT), a global diagnostics company, and will be launched this fall. Originally, this agreement was a $885 million partnership between Freenome and Exact Sciences, signed in August 2025, but it was amended when Abbott acquired Exact Sciences for $23 billion. With this FDA approval, Abbott will fulfill the $100 million milestone payment to Freenome, further solidifying the commercial relationship between the two companies. Through Abbott's hospital and diagnostics center sales network, the market penetration of SimpleScreen CRC in the U.S. is expected to be rapid.
Paradigm Shift in the Diagnostics Market and Future Prospects
The global colorectal cancer blood screening market is projected to grow from $2.8 billion in 2025 to $8.6 billion in 2034, with an annual growth rate of 13.2%, making it a high-growth sector. Freenome has secured its position as the second company to receive FDA approval for a colorectal cancer blood test, following Guardant Health's (GH) Shield™, which was approved in July 2024. While it shows similar performance to Shield, with a sensitivity of 83% and a specificity of 90%, its differentiation lies in Abbott's strong sales capabilities and the ability to meet the requirements for Medicare reimbursement.
In the future, liquid biopsy technology is expected to play a gateway role in guiding patients to undergo more precise examinations, rather than completely replacing colonoscopies, and will drive the market.
Freenome's SimpleScreen CRC approval, as the second FDA-approved colorectal cancer blood screening test after Guardant Health's Shield, is a pivotal milestone that will reshape the landscape of the blood-based diagnostics market, projected to reach $8.6 billion by 2035. The sensitivity of 81.1% and specificity of 90.4% demonstrated in the PREEMPT CRC prospective clinical trial involving 48,000 participants will serve as scientific evidence for future inclusion in the American Cancer Society guidelines and expansion of Medicare reimbursement coverage. With this approval, Abbott has significantly strengthened its colorectal cancer screening portfolio following the acquisition of Exact Sciences, positioning itself for a leading role in market share competition. In the short term, Freenome's financial stability will be enhanced by the $100 million milestone payment upon FDA approval, and in the medium to long term, rapid market penetration is expected among the 60 million Americans who are not currently undergoing screening. However, the sensitivity of 13.7% in detecting advanced precancerous lesions remains a challenge for blood-based diagnostic technology, and researchers are expected to focus on strengthening multi-omics technology to improve early detection rates in the future.